Recognizing the journey of heme/onc pharmacists—starting & enduring alongside patients and physicians but not seeing the end. Check out this insightful piece by @KB_McCullough in @JCO_ASCO https://t.co/dmvA9NrIPS #Oncology#PharmacyHeroes#oncopharm
@BonumCe@Global_CME@NoopurRajeMD@mvmateos@MaiolinoAngelo@jayrsf_ 18/ 🚩There are limited open clin trial sites in🇺🇸 states w/ the highest % of Black residents
🚩2/4 🇺🇸 states where >30% of population is Black ppl had 🚫no CAR-T or bispecific clinical trial openings
34% of the 🇺🇸 states had 🚫no CAR-T or bispecific clinical trial openings
#mmsm
@EmilyMackler@YesRxMichigan This is amazing @EmilyMackler ! Love that you found a way for patients who have unopened, unused cancer 💊 they no longer need to share with patients who can't afford 💰 to buy much needed cancer💊 #cancer#disparities
Friends - Exciting update from @yesrxmichigan ! We received our non-profit status and are eager to serve #Michiganders who are having difficulty affording their meds. Consider helping us by donating here! https://t.co/5Mc7YnwijO #cancer#oncology#financialtoxicity
AMWA-MAC is proud to announce that Julianna Merten (@ChimericMed ) will speak on critical thinking at our 2023 Annual Conference!
Register today at
https://t.co/zWiibwGyhk
View the conference schedule at
https://t.co/m3HtuEUWtI
#AMWAMAC2023
In patients who have had a median of 6 prior lines of therapy, the response rate with cilta-cel is 98%.
Stringent complete responses in 83%. So you can see why the myeloma field is optimistic.
Accepting mediocrity in leadership in mid levels because you want people who are nice and compliant to orders from top means you end up with mediocrity in leadership in high levels in course of time.
#leadershipmatters